Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2

Brilliant. Reached the 23 patient milestone. Review of Safety data triggered.

3 patients in a week since the last update with only 5 of the activated sites.

With 10 activated sites this trial will be over well before the 18 month time line.

Patient permission is no problem/hinderence. Who wouldn't want to say "yes please ! " given the safety data.

Also while the trial is progressing at pace we have :

"In parallel, the Company is investigating the potential utility of ARG-007 in other neurological
conditions. Underpinning this research, over $4 million in non-dilutive grant and philanthropic
funding has been secured throughout the life of the projects from the Federal and Western
Australian governments, the Stan Perron Charitable Foundation, the McCusker Foundation,
and donors to the Perron Institute."

Traumatic Brain Injury, Alzheimers and HIE all getting prepped for Phase 2 trials non dilutive funded by others.